Document is current

Any future updates will be listed below

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

Crossref DOI link: https://doi.org/10.1007/s10637-014-0121-6

Published Online: 2014-06-01

Published Print: 2014-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark